Learn / Antidepressants
Antidepressants
Antidepressants, without the marketing or the panic
Why antidepressants are prescribed, why their effects are delayed, which adverse effects people actually report, and why stopping is itself a medication event.
Antidepressants are among the most commonly prescribed medicines in Australia. They are also among the most argued-over. This page is not a brief for or against them. It is a map of what the literature actually supports, and what it does not.
Classes you will meet
- SSRIs — sertraline, escitalopram, fluoxetine, paroxetine, fluvoxamine, citalopram.
- SNRIs — venlafaxine, desvenlafaxine, duloxetine.
- Others, at a high level — mirtazapine, agomelatine, vortioxetine, bupropion. These are not interchangeable with SSRIs, and this site does not treat them as a single story.
Delayed effect, ordinary adverse effects
Therapeutic benefit, when it occurs, is often delayed by weeks. Adverse effects can arrive earlier: gastrointestinal change, sleep change, sexual side-effects, sweating, headache, restlessness. Activation — feeling wired, agitated, or unusually energised — is a recognised early reaction in some people and is a reason to speak with the prescriber, not a reason for a website to guess a diagnosis.
1 · Statement
Some people taking SSRIs report that emotions become less intense — both the difficult ones and the ones they wanted to keep. That experience is documented in qualitative research. It is not universal.
2 · Classification
Associated. Strong qualitative signal; incidence in routine care is less precisely known.
3 · Papers
4 · Claim limitation
Qualitative attribution is not a population rate.
Last reviewed
1 September 2026
Stopping is a medication event
For many antidepressants, staged dose reduction is commonly recommended. Abrupt cessation can be followed by discontinuation symptoms. Those symptoms can look like anxiety, like influenza, like the original illness, or like something new. Relapse and withdrawal can resemble one another. A website cannot tell them apart for you.
1 · Statement
Stopping or reducing many antidepressants can be followed by discontinuation symptoms in a substantial minority of people. Estimates of how often this happens vary widely by study method. Withdrawal is not the same as addiction, and it is not automatically the same as relapse.
2 · Classification
Established. Recognised in guidelines. Incidence estimates differ (survey syntheses vs placebo-adjusted meta-analysis).
3 · Papers
4 · Claim limitation
Symptoms overlap with relapse, anxiety and sleep disruption. Individual attribution remains uncertain.
Where evidence disagrees
Davies and Read (2019) reported withdrawal incidence estimates from 27% to 86% across mixed study designs, with a weighted average of 56%. Henssler et al. (2024), after accounting for symptoms also reported after stopping placebo, estimated about 15%, with severe symptoms in about one in 35. Both papers stay in this library. The disagreement is the finding. Incidence is not causation in an individual, and neither estimate is a tapering schedule.
Last reviewed
1 September 2026
1 · Statement
For many antidepressants, staged dose reduction is commonly recommended rather than abrupt cessation. Paradoxical.life does not provide an individual tapering schedule.
2 · Classification
Established. Present in major depression guidelines and in discontinuation literature.
3 · Papers
4 · Claim limitation
How slowly, and with which formulation, is an individual clinical decision.
Last reviewed
1 September 2026
Sources used on this page
- National Institute for Health and Care Excellence (NICE) (2022). Depression in adults: treatment and management (NG222).
- Horowitz MA, Taylor D (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms.
- Davies J, Read J (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?.
- Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C (2024). Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
- Price J, Cole V, Goodwin GM (2009). Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study.
Paradoxical.life provides evidence and self-documentation tools, not medical advice. If you have concerns about your health, medication or mental state, speak with a qualified medical practitioner.